MWNA
TVRD

Marshall Wace North America’s Tvardi Therapeutics TVRD Stock Holding History

Marshall Wace North America’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-838
Closed -$384K – 1641
2020
Q3 		$384K Sell
838
-1,242
-60% -$721K ﹤0.01% 1023
2020
Q2 		$1.28M Buy
+2,080
New +$1.15M 0.01% 698
2019
Q1 		– Sell
-565
Closed -$265K – 1968
2018
Q4 		$265K Buy
+565
New +$364K ﹤0.01% 901
2018
Q3 		– Sell
-1,026
Closed -$707K – 1437
2018
Q2 		$707K Buy
+1,026
New +$522K ﹤0.01% 1016

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Marshall Wace North America's TVRD Position: Q4 2020 in Review

Marshall Wace North America sold out of Tvardi Therapeutics (TVRD) in Q4 2020, closing a stake of 838 shares — an estimated $384K sold.

Marshall Wace North America first reported a position in TVRD in Q2 2018 and held it in 4 quarters. The position peaked at $1.28M in Q2 2020. 156 funds tracked by Wall St. Rank hold TVRD as of Q4 2020.

  • Marshall Wace North America reported no remaining Tvardi Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Marshall Wace North America sold 838 Tvardi Therapeutics shares in Q4 2020, an estimated $384K.
  • Marshall Wace North America first reported a position in Tvardi Therapeutics in Q2 2018 and held it in 4 quarters.
  • Marshall Wace North America's Tvardi Therapeutics position peaked at $1.28M in Q2 2020.
  • 156 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2020.

Based on Marshall Wace North America's 13F filing for Q4 2020, filed 16 Feb 2021.